| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05113537) | Vadim S Koshkin | 2022-07-08 |
| Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT05479578) | Rashmi Verma, MD | 2022-06-29 |
| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer (NCT05547386) | Mayo Clinic | 2022-05-09 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05168618) | University of Utah | 2022-03-29 |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05037500) | Roswell Park Cancer Institute | 2022-01-26 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones (NCT04616547) | National Cancer Institute (NCI) | 2021-12-18 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (NCT04455750) | Alliance for Clinical Trials in Oncology | 2021-10-14 |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer (NCT04716725) | Thomas Hope | 2021-09-28 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer (NCT04754425) | M.D. Anderson Cancer Center | 2021-07-15 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer (NCT04489719) | University of Washington | 2021-04-16 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT04471974) | Rahul Aggarwal | 2021-01-26 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer (NCT04592237) | M.D. Anderson Cancer Center | 2020-12-29 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer (NCT03999515) | University of Washington | 2020-04-27 |
| Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer (NCT04279561) | Jonsson Comprehensive Cancer Center | 2020-04-16 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (NCT03503344) | University of California, San Francisco | 2019-12-17 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04033432) | Northwestern University | 2019-09-20 |
| PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (NCT03873805) | City of Hope Medical Center | 2019-08-20 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03751436) | Roswell Park Cancer Institute | 2019-08-02 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03517969) | National Cancer Institute (NCI) | 2019-05-29 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03805594) | University of California, San Francisco | 2019-05-10 |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (NCT03317392) | National Cancer Institute (NCI) | 2019-02-04 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (NCT03582475) | Jonsson Comprehensive Cancer Center | 2019-01-11 |
| Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (NCT03344211) | University of Southern California | 2018-11-21 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer (NCT03516812) | University of Washington | 2018-08-29 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency (NCT03442556) | University of Washington | 2018-08-24 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy (NCT03596710) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03406858) | Barbara Ann Karmanos Cancer Institute | 2018-06-07 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer (NCT03456804) | Barbara Ann Karmanos Cancer Institute | 2018-03-08 |
| Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCT03360721) | M.D. Anderson Cancer Center | 2018-03-06 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer (NCT03448458) | Emory University | 2018-02-22 |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (NCT02893917) | National Cancer Institute (NCI) | 2017-08-11 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCT03217747) | M.D. Anderson Cancer Center | 2017-08-02 |
| Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03204812) | M.D. Anderson Cancer Center | 2017-07-14 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02703623) | M.D. Anderson Cancer Center | 2016-05-18 |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02565901) | University of Washington | 2016-02-29 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway (NCT02598895) | University of Washington | 2016-01-26 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT02532114) | University of Washington | 2015-12-31 |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression (NCT02555189) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-12-01 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (NCT02522715) | OHSU Knight Cancer Institute | 2015-08-13 |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide (NCT02312557) | OHSU Knight Cancer Institute | 2014-11-18 |
| Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy (NCT02099864) | OHSU Knight Cancer Institute | 2014-02-05 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01881867) | Fred Hutchinson Cancer Center | 2013-09-10 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide (NCT02228265) | OHSU Knight Cancer Institute | 2013-03-12 |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01576172) | National Cancer Institute (NCI) | 2012-03-30 |